About Rebus Biosystems
Rebus Biosystems is a company based in Santa Clara (United States) founded in 2006 by Ron Cook and Josh Ryu. Rebus Biosystems has raised $20 million across 2 funding rounds from investors including HHS, Seegene Technologies and Lifecore. Rebus Biosystems operates in a competitive market with competitors including 10X Genomics, Mission Bio, Singleron, Cellares and LUMICKS, among others.
- Headquarter Santa Clara, United States
- Founders Ron Cook, Josh Ryu
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$20 M (USD)
in 2 rounds
-
Latest Funding Round
$20 M (USD), Series B
Nov 19, 2020
-
Investors
HHS
& 8 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Rebus Biosystems
Unlock access to complete
Unlock access to complete
Funding Insights of Rebus Biosystems
Rebus Biosystems has successfully raised a total of $20M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $20 million completed in November 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Rebus Biosystems
Rebus Biosystems has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include HHS, Seegene Technologies and Lifecore.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health tech startups are invested in by Illumina Ventures.
|
Locked | Locked | Locked | |
|
Early-stage startups are funded by Seoul-based Ncore Ventures.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Rebus Biosystems
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Rebus Biosystems
Investment portfolio details for Rebus Biosystems
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Rebus Biosystems
Detailed financials for Rebus Biosystems
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Rebus Biosystems Comparisons
Peer comparison for Rebus Biosystems
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Rebus Biosystems
Rebus Biosystems operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as 10X Genomics, Mission Bio, Singleron, Cellares and LUMICKS, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Instrument systems for genomic research and sequencing libraries are developed.
|
|
| Locked | Locked | Locked |
Single-cell multi-omics platform is provided for genotypic and phenotypic analysis.
|
|
| Locked | Locked | Locked |
Developer of single-cell multi-omics platform for clinical research and molecular diagnosis
|
|
| Locked | Locked | Locked |
Medical devices for cell-based therapy manufacturing are produced.
|
|
| Locked | Locked | Locked |
Optical tweezers instruments for single-molecule analysis are manufactured.
|
|
| Locked | Locked | Locked |
Single-cell imaging platform developed via magnetic levitation technology.
|
Detailed competitors of Rebus Biosystems
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Rebus Biosystems
Complete news archive for Rebus Biosystems
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rebus Biosystems
Rebus Biosystems was founded in 2006 and raised its 1st funding round 3 years after it was founded.
Rebus Biosystems is headquartered in Santa Clara, United States. It is registered at Santa Clara, California, United States.
Paul Sargeant is the current CEO of Rebus Biosystems.
Rebus Biosystems is a funded company, having raised a total of $20M across 2 funding rounds to date.
Founded in 2006 and based in Santa Clara, United States, operations focus on biotechnology and spatial omics. Patented Synthetic Aperture Optics technology is utilized for analyzing multiple gene expressions in single cells, enabling subcellular resolution imaging of full tissue sections via laser beams. The Rebus Esper platform is integrated with advancements in imaging, fluidics, chemistry, and bioinformatics to provide spatial omics data.
Rebus Biosystems's top competitors include 10X Genomics, Mission Bio and Cellares.
Rebus Biosystems has 9 investors. Key investors include HHS, Seegene Technologies, Lifecore, Illumina Ventures, and Ncore Ventures.